The global Blood Testing market size was valued USD 80.50 billion in 2021 and is expected to rise to USD 128.45 billion by 2028 at a CAGR of 8.10%.
The global blood testing market size was worth USD 80.50 billion in 2021 and is estimated to grow to USD 128.45 billion by 2028, with a compound annual growth rate (CAGR) of approximately 8.10 percent over the forecast period. The report analyzes the blood testing market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the blood testing market.
Blood tests are the most basic diagnostic method used to determine the malfunction of the human system. Regular blood tests are the easiest way to track your health. It is essential to have regular blood tests for good health and to make informed decisions about health in particular. Blood tests are also important to reduce the risk of various illnesses and related complications. Increased government and regulatory healthcare costs are expected to drive the market during the forecast period. Therefore, governments and key organizations constantly strive to encourage patients to undergo regular diagnostic tests. Furthermore, recent advances, the regulatory approval process, and a lack of awareness of the high cost of automated blood tests will hinder market growth over the next few years. Multinational healthcare institutions can help discover new technologies and raise awareness for eradicating & diagnosing common and chronic diseases. Solid external funding for clinical trials being conducted to develop new and innovative diagnostic tests is expected to boost the market. The introduction of constructive regulatory parameters to encourage POC tests is a major rendering driver on the market.
With the exponential increase in the number of COVID-19 cases worldwide, the demand for large diagnostic tests is increasing. Prompt diagnosis, effective treatment options, and future prevention plans are essential for the management of COVID-19. The current competition to develop test kits that enable proximity detection of coronavirus infections at low cost has brought about rapid innovation in diagnosis. In July 2020, Washington doctors examined the blood of people affected by COVID-19 to identify patients at high risk of developing serious illnesses and artificially ventilate patients under treatment.
Regulators such as the FDA, Medicare and Medicaid Service Center (CMS), and the Federal Trade Commission play an important role in regulating diagnostic tests. These agencies have taken the initiative to commercialize clinical laboratory improvement and modification compliant diagnostic tests that may help in the early detection of illness. The introduction of CLIA in the United States is expected to increase blood test used during the prediction period.
Rigid regulatory approval strategies are likely to hamper the market growth in the coming years. In the U.S., the development of commercial trials is regulated by the U.S. Food and Drug Administration (U.S. FDA). The US FDA is responsible for approving the use of clinical tests. Lack of awareness of the development of new technologies and procedures related to blood tests will hamper the market over the forecast period.
The global blood testing market is segregated based on test type, end-use, method, and region.
By test type, the market is divided into lipid panel testing, prostate-specific, antigen, COVID-19, complete blood count (CBC), BUN testing (blood urea nitrogen), glucose testing, A1C, direct LDL, cortisol, creatinine, and other tests. Among these, the glucose testing segment dominates the market owing to technological advances in these glucose meters, etc. Wireless connectivity and Bluetooth capabilities further drive the market acceptance of these products. iHealth Smart, iHealth Align, Dario Health Smart Meter and Glooko are examples of smart blood glucose monitoring products.
By end user, the market is classified into hospitals, clinics, diagnostic centers, research laboratories, and others (blood banks). Over the forecast period, the research laboratories segment is expected to develop at the fastest rate. Laboratory tests of blood and blood products provided for infections are an important safety measure to protect patients and prevent the spread of serious infections. Factors such as increased blood donation & blood transfusion-related screening, increased awareness of blood transfusion-related infectious diseases, and increased incidence of infectious diseases are driving the growth of this segment.
By method, the market is classified into manual and automated. The automated segment dominates the market.
Increasing the number of strategic initiatives taken by government agencies and market players to increase blood donations across the region is one of the factors expected to drive North America market growth. Blood centers across the country are stepping up efforts to collect blood from people who have recovered from their illnesses. Several organizations, such as the New York Blood Center, American Red Cross, AABB, America's Blood Centers, Armed Services Blood Program, and Blood Centers of America, provide information on plasma collection and plasma delivery. Increased blood donations are expected to further drive demand for testing products for pre-transplant and post-transplant procedures. In the Asia Pacific region, the blood testing market is expected to show the fastest CAGR during the forecast period. The increasing prevalence of chronic diseases in developing countries such as India and China is a major driver of market growth.
Some of the main competitors dominating the global blood testing market include - Richard Wolf GmbH, WISAP Medical Technology, KARL STORZ GmbH & Co. KG, Stryker, Teleflex Inc. Ethicon LLC, Centrel, OPTOMIC, Medgyn Products, Inc., Maxer Endoscopy, Vimex Sp. z o.o, Olympus Corporation, and Henke-Sass Wolf.
By Test Type
By End User
By Method
By Region
FrequentlyAsked Questions
The blood testing market has expanded dramatically due to the impact of ageing around the world is driving the market growth. The number of strategies in the global market has increased dramatically in recent years, leading to an expansion of the market leader's product portfolio and a stronger market presence. In addition, blood tests increase in other diagnostic areas and develop various diseases such as bacterial and viral allergic diseases, thyroid diseases, human immunodeficiency virus (HIV) infections, hereditary diseases, cancer and hepatitis. Additional factors, such as higher rates, will propel the market growth during the forecast period.
According to the report, the global blood testing market was worth 80.50 (USD billion) in 2021 and is predicted to grow to 128.45 (USD billion) by 2028, with a compound annual growth rate (CAGR) of around 8.10 percent.
North America will dominate the blood testing market in the coming years. Due to the increased incidence of diseases such as kidney disease, bloodstream infections and other infections, the high demand for rapid diagnostic testing, and the ageing population, the North American region has become a medical test in the global blood testing market has the largest market share over the forecast period.
Some of the main competitors dominating the global blood testing market include - Richard Wolf GmbH, WISAP Medical Technology, KARL STORZ GmbH & Co. KG, Stryker, Teleflex Inc. Ethicon LLC, Centrel, OPTOMIC, Medgyn Products, Inc., Maxer Endoscopy, Vimex Sp. z o.o, Olympus Corporation, and Henke-Sass Wolf.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed